Stoke Therapeutics boosts a protein linked to inherited blindness, but can STK-002 save vision?
Stoke Therapeutics reports STK-002 OPA1 protein gains as Phase 1 OSPREY advances. Examine the evidence, safety questions and 2027 readout.
Pharma & Biotech